Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2009

Clovis Oncology Raises $145M in Start-Up Financing

Clovis Oncology Raises $145M in Start-Up Financing

Clovis raises $145M in start-up funds

  • Clovis Oncology, a newly formed company focused on acquiring, developing, and commercializing anti-cancer agents, has secured $145 million in start-up financing.

    Founded by former executives of Pharmion Corporation, which was acquired by Celgene in 2008 for $2.9 billion, Clovis says it intends to acquire rights to or license innovative anti-cancer compounds in all stages of clinical development, and develop and market them in the U.S. and Europe.

    "Clovis is focused on partnering with these discovery-based companies and taking responsibility for developing and commercializing innovative products that may ultimately provide significant benefit to cancer patients," says Patrick J. Mahaffy, Clovis' president and CEO.

    Investors in Clovis include Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company's management team.ADNFCR-2184-ID-19181278-ADNFCR

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »